Antagonist anti-CD89 zal worden ontwikkeld voor de behandeling van lineaire IgA bulleuze dermatose.

WARSCHAU, Polen–(BUSINESS WIRE)– JJP Biologics, een bedrijf dat gespecialiseerd is in de ontwikkeling van gepatenteerde biologische middelen voor gepersonaliseerde geneeskundebenaderingen, heeft aangekondigd dat de Europese Commissie de aanvraag van het bedrijf voor aanwijzing van zijn product kandidaat JJP-1212 als een weesgeneesmiddel voor de behandeling van lineaire IgA bulleuze dermatose (LABD). In navolging van de aanbeveling van het Europees Geneesmiddelenbureau heeft de Europese Commissie bevestigd dat het voornemen om deze aandoening te behandelen met JJP-1212 de status van weesgeneesmiddel rechtvaardigde op basis van in vitro en in vivo niet-klinische gegevens die de vermindering van de instroom van granulocyten in het basaalmembraan aantonen zone van de huid en vermindering van inflammatoire biomarkers, waarbij de belangrijkste elementen van de pathogenese van LABD-blaarvorming op de huid worden aangepakt.

JJP Biologics: The European Commission Has Designated JJP-1212 as an Orphan Medicinal Product.

Antagonist anti-CD89 will be developed for the treatment of Linear IgA Bullous Dermatosis.

WARSAW, Poland–(BUSINESS WIRE)– JJP Biologics, a company that specializes in the development of proprietary biologic agents for personalized medicine approaches, has announced that the European Commission has approved the company’s application for designation of its product candidate JJP-1212 as an orphan medicinal product for treatment of Linear IgA Bullous Dermatosis (LABD). Following the European Medicines Agency’s recommendation, the European Commission has confirmed that the intention to treat this condition with JJP-1212 justified orphan drug status based on in vitro and in vivo non-clinical data showing the reduction in the influx of granulocytes into the basement membrane zone of the skin and reduction of inflammatory biomarkers, addressing the key elements of LABD skin blistering pathogenesis.

LABD is a chronically debilitating disease and may lead to blindness and blister formation. Moreover, currently no approved treatments are available for LABD in the European Union. The European Commission has confirmed that, as of the day of submitting the application, LABD could affect approximately 0.3 in 10,000 persons in the European Union.¹

“The orphan drug designation of JJP-1212 by the EMA validates the scientific and business choices of JJP Biologics. It was confirmed that JJP-1212 targets the central mechanism in LABD by antagonizing the IgA-CD89 interaction” according to Louis Boon, the Chief Scientific Officer at JJP Biologics. “We are very excited to offer a potential novel therapy for patients suffering from this ultra-rare skin disease with currently unmet needs”.

Having this drug classified into the group of orphan medicinal products provides scientific advice and protocol assistance of the agency. “This decision by the European Commission has also a substantial streamlining effect on the clinical development timeline. We feel the responsibility to translate this decision into prompt availability of the therapy for patients” states Paweł Szczepański, the Chief Operations Officer at JJP Biologics.

About JJP Biologics:

JJP Biologics sp. z o.o. is a biotechnology company that specializes in the development of proprietary biologic agents accompanied by companion diagnostics to allow therapy personalization. JJP Biologics is a privately funded biotech which pursues the development of its own product candidates as well as projects executed in cooperation with scientific partners. The company’s programs target general immune pathways that have application in autoimmune diseases and cancer. JJP Biologics currently has a range of programs including the most advanced JJP-1212 program and an anti-CD270 program for immune oncology. https://jjpbiologics.com/

¹ JJP Biologics performed a systematic review of the published literature and the relevant EU databases (list items)

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018006075/en/

Contacts

Bartłomiej Kupiec

M: +48 604 542 348

@: bartlomiej.kupiec@secnewgatecee.com